---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-027730"
form_type: "8-K"
ticker: "ENSC"
cik: "0001716947"
company_name: "Ensysce Biosciences, Inc."
filed_at: "2023-08-11T23:59:59+00:00"
generated_at: "2026-06-11T14:47:47.442299+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Ensysce Biosciences Q2 net loss $2.2M; cash $3.8M; IRB approves key PF614 study

## Summary
- Net loss for Q2 2023 was $2.2 million versus $7.9 million in Q2 2022; EPS ($0.98) vs ($56.49).
- Cash and cash equivalents $3.8 million at June 30, 2023, up from $1.4 million at March 31; increase driven by May 2023 public offering with $7.0 million gross proceeds.
- R&D expenses decreased to $1.6 million in Q2 2023 from $5.3 million in Q2 2022 due to timing of clinical studies.
- IRB approval received for PF614-201 protocol, a key Phase 3 study; End of Phase 2 meeting with FDA anticipated later this year.
- Positive results from oral abuse potential study (PF614-104) and overdose protection Phase 1 study (PF614-MPAR-101) completed.

## SEC filing metadata
- accession: 0001493152-23-027730
- form_type: 8-K
- ticker: ENSC
- cik: 0001716947
- company_name: Ensysce Biosciences, Inc.
- filed_at: 2023-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716947/000149315223027730/0001493152-23-027730-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716947/000149315223027730/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-027730
- JSON: https://secwatch.observer/filing/0001493152-23-027730.json
- Plain text: https://secwatch.observer/filing/0001493152-23-027730.txt

## Key facts
- Earnings Releases
  Ensysce Biosciences, Inc. reported the second quarter of 2023 results: net income Net loss attributable to common stockholders for the second quarter of 2023 was $2.2 million.
  - Period: the second quarter of 2023
  - Net income: Net loss attributable to common stockholders for the second quarter of 2023 was $2.2 million
  - Result: reported results
  source text: On August 11, 2023, Ensysce Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1716947/000149315223027730/0001493152-23-027730-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.